Melinta's Vabomere has greater overall success rate vs piperacillin-tazobactam
Melinta Therapeutics announced that results from the Phase 3 TANGO I study of Vabomere for injection were published in the Journal of the American Medical Association, or JAMA. Vabomere was approved by the FDA in August 2017 for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae species complex. The Targeting Antibiotic Non-susceptible Gram-negative Organisms, or TANGO 1, trial was the pivotal Phase 3 study that compared the efficacy and safety of Vabomere to piperacillin-tazobactam in the treatment of patients with cUTI and acute pyelonephritis. As initially reported in a June 2016 top-line analysis, the results of TANGO I demonstrated that Vabomere was non-inferior to piperacillin-tazobactam with overall success in 98.4% of treated patients compared with 94.0% following treatment with piperacillin-tazobactam using the FDA primary endpoint of clinical cure plus microbiological eradication at the end of IV treatment.